Enesi Pharma is a new clinical-stage pharmaceutical company developing a range of unique, injectable solid dose, drug-device combination products.
Enabled by its proprietary ImplaVax™ formulation and device technologies, data suggests that these products have the potential to transform the immune response performance and delivery of vaccines and therapeutics and make a material impact on global healthcare.
These innovative products offer significant potential benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and are supported by a strong patient preference over a standard needle and syringe.
Enesi’s primary focus is the development of novel solid dose vaccines against a range of infectious and autoimmune diseases, working in partnership with global companies, government agencies and non-governmental organisations.
Enesi’s experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders.